



Diagnosis and Management of HIV-2 in Adults

July 2019

Table 1: ART Regimens for Initial Treatment of Nonpregnant Adults With HIV-2*	
PREFERRED Regimens	
Single-Tablet Regimens	Comments
Abacavir/lamivudine/dolutegravir (ABC/3TC/DTG; Triumeq)	<ul style="list-style-type: none"> Initiate only in patients confirmed to be negative for HLA-B*5701. Initiate only in patients with creatinine clearance (CrCl) \geq50 mL/min. Consider underlying risk of coronary heart disease. Documented DTG resistance after initiation in treatment-naive patients is rare. Clinicians should refer to the DHHS <i>Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States</i> when choosing an initial regimen for individuals of childbearing potential. In patients with HIV/HBV coinfection, this regimen should be used in conjunction with other anti-HBV drugs.
Tenofovir alafenamide/emtricitabine/bictegravir (TAF 25 mg/FTC/BIC; Biktarvy)	<ul style="list-style-type: none"> Initiate only in patients with CrCl \geq30 mL/min. Contains 25 mg of TAF, unboosted.
ALTERNATIVE Regimens	
Single-Tablet Regimens	Comments
Tenofovir alafenamide/emtricitabine/cobicistat/darunavir (TAF 10 mg/FTC/COBI/DRV; Symtuza)	<ul style="list-style-type: none"> Initiate only in patients with CrCl \geq30 mL/min. Carefully consider drug-drug interactions with COBI [Eron, et al. 2018]. Contains 10 mg TAF, boosted.
Tenofovir alafenamide/emtricitabine/cobicistat/elvitegravir (TAF 10 mg/FTC/COBI/EVG; Genvoya)	<ul style="list-style-type: none"> Initiate only in patients with CrCl \geq30 mL/min. Carefully consider drug-drug interactions with COBI. Contains 10 mg of TAF, boosted with COBI.
Once-Daily Multi-Tablet Regimens	Comments
Abacavir/lamivudine <i>and</i> raltegravir (ABC/3TC <i>and</i> RAL HD; Epzicom <i>and</i> Isentress HD)	<ul style="list-style-type: none"> Initiate only in patients confirmed to be negative for HLA-B*5701 and negative for HBsAg. Consider underlying risk of coronary heart disease. ABC/3TC once daily, RAL HD 1200 mg once daily dosed as two 600 mg HD tablets.
Tenofovir alafenamide/emtricitabine <i>and</i> darunavir <i>and</i> ritonavir (TAF/FTC <i>and</i> DRV/RTV; Descovy <i>and</i> Prezista <i>and</i> Norvir)	<ul style="list-style-type: none"> Carefully consider drug-drug interactions with RTV. Initiate only in patients with CrCl \geq30 mL/min. Contains 25 mg TAF, boosted. Use with caution in individuals with stage 3 chronic kidney disease.



CLINICAL GUIDELINES PROGRAM

NEW YORK STATE DEPARTMENT OF HEALTH AIDS INSTITUTE | HIV · HCV · SUBSTANCE USE · LGBT HEALTH

Table 1: ART Regimens for Initial Treatment of Nonpregnant Adults With HIV-2*

<p>Tenofovir alafenamide/emtricitabine <i>and</i> darunavir/cobicistat (TAF/FTC <i>and</i> DRV/COBI; Descovy <i>and</i> Prezcoibix)</p>	<ul style="list-style-type: none"> Carefully consider drug-drug interactions with COBI. Initiate only in patients with CrCl \geq30 mL/min. Contains 25 mg TAF, boosted. Use with caution in individuals with stage 3 chronic kidney disease.
<p>Tenofovir alafenamide/emtricitabine <i>and</i> dolutegravir (TAF 25 mg/FTC <i>and</i> DTG; Descovy <i>and</i> Tivicay)</p>	<ul style="list-style-type: none"> Initiate only in patients with CrCl \geq30 mL/min. Documented DTG resistance after initiation in treatment-naive patients is rare. Contains 25 mg of TAF, unboosted. Clinicians should refer to the DHHS <i>Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States</i> when choosing an initial regimen for individuals of childbearing potential.
<p>Tenofovir alafenamide/emtricitabine <i>and</i> raltegravir (TAF 25 mg/FTC <i>and</i> RAL HD; Descovy <i>and</i> Isentress HD)</p>	<ul style="list-style-type: none"> Initiate only in patients with CrCl \geq30 mL/min. To date, no clinical trials have been conducted with TAF; data are based on bioequivalence pharmacokinetic studies. Contains 25 mg of TAF, unboosted. TAF/FTC once daily and RAL HD 1200 mg once daily dosed as two 600 mg HD tablets.
<p>*Listed alphabetically; see prescribing information for individual drugs. Notes: 1) In all cases, FTC and 3TC are interchangeable when not being used in fixed-dose combinations; 2) Because of their drug interaction profiles, COBI and RTV should not be considered interchangeable; 3) TAF 10 mg and TAF 25 mg are not interchangeable; and 4) Refer to <i>Table 8: ARV Dose Adjustments for Renal and Hepatic Impairment</i> in the NYSDOH AI guideline <i>Selecting an Initial ART Regimen</i> for adjustment based on renal or hepatic function.</p>	

Reference

Eron JJ, Orkin C, Gallant J, et al. A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. *AIDS* 2018;32(11):1431-1442. [PMID: 29683855] <https://www.ncbi.nlm.nih.gov/pubmed/29683855>